Conjunctivitis Market (By Type: Bacterial Conjunctivitis, Viral Conjunctivitis, and Allergic Conjunctivitis; By Patients Type: Pediatric and Adults; By Drug Class: Antibiotics, Anti-Histaminic, Decongestant, Steroid Drugs, and Others) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2023 - 2032
The global conjunctivitis market size was estimated at USD 4.80 billion in 2022 and is predicted to surpass around USD 8.08 billion by 2032, expanding immensive CAGR of 5.40% during the estimate period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. conjunctivitis market size accounted for USD 1.11 billion in 2022 and is projected to grow around USD 1.88 billion by 2032, at a CAGR of 5.40% from 2023 to 2032.
North America is Estimated to be the Largest Market for Conjunctivitis
The detailed research report covers significant prospects and inclinations of conjunctivitis products throughout different regions including Europe, North America, Asia-Pacific, Africa, Middle East, and Latin America. By region, conjunctivitis market is led by North America due to early application of latest technologies and availability of latest technology infrastructure. Europe reported the second maximum share predominantly due to presence of key companies. Asia-Pacific is also anticipated to witness the rapid growth rate, on account of increasing healthcare expenditure.
Major Trends in the Conjunctivitis Industry:
Patents on medication such as Lotemax, Patanol, Pataday, and Lastacaft are expected to expire during the forecast period, as well as other medications. Though the frequency of conjunctivitis is higher, the rate of treatment use is not, as the contamination usually rectifies on its own. Treatment is usually sought only when the condition persists or when the infection starts affecting the daily activities of an individual. As the infection is highly contagious, proper maintenance of hygienic conditions is necessary.
Conjunctivitis, also known as pink eye, is an infection in or irritation of the conjunctiva. It disturbs a person's eyes and might be the result of a virus, bacteria, or allergen. Allergens such as pollen, smoke, eye drops, dust mites, perfumes, and cosmetics can result in conjunctivitis. It is typically associated with soreness of the eye accompanied by the release of mucous releases. Although the ailment usually heals without medicine, antibiotics are usually used for treatment to avoid problems due to irritation of the eye.
The timely use of medication to treat the condition helps keep it under control. This can be ensured through educating people about the condition and conducting awareness campaigns. For instance, as part of the efforts of the Lebanese Ministry of Public Health and the Lebanese Ministry of Education and Higher Education, the University of Balamand's Faculty of Health Sciences conducted a conjunctivitis awareness campaign for the students, faculty, and staff of the university. Similarly, Planned Parenthood Arizona published a report about the connection between sexually transmitted infections and conjunctivitis. Educating the public on the treatment options for conjunctivitis increases the chances of individuals identifying the infection and treating it early with medication.
Treatment depends on the stage of conjunctivitis along with the experience of the optometrist. Experienced physicians understand the root cause of the condition easily, which helps reduce the patient's intake of unnecessary medication. Proper treatment reduces the incidence of the condition and avoids the chances of the condition worsening. The treatment options available for conjunctivitis are as follows
Crucial factors accountable for market growth are:
COVID-19 Impact on Global Conjunctivitis Market
Most of the leading nationswere forced into lockdown in order to control the coronavirus outbreak. That has led to disruption in the industry's supply chain. Because of this situation, most of the pharmaceutical companies globally are currently concentrating on saving their commerce and cash flow, instead of investing in manufacturing products.Key companies operating in the worldwide conjunctivitis industry are also facing issues to run their facilities and operate at full capacity to achieve their production target.
Report Highlights | Details |
Market Size | USD 8.08 billion by 2032 |
Growth Rate | CAGR of 5.40% From 2023 to 2032 |
Base Year | 2022 |
Historic Data | 2019 to 2021 |
Forecast Period | 2023 to 2032 |
Segments Covered | Patients, Drug Class, Patients Type |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Companies Mentioned | Atopix Therapeutics Ltd., Allegran, Ocular Therapeutix, Inc., Santen Pharmaceutical Co. Ltd., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, Sirion Therapeutics, Inc. |
Allergic Conjunctivitis Segment Reported Foremost Market Stake in 2022
The allergic conjunctivitis displayed the major share in the worldwide conjunctivitis market in 2022. High prevalence of allergic conjunctivitis due to high exposure to allergen are the key reason for highest market stake of software segment. The factors such as strong product pipeline and high R&D expenditure are expected to retain the dominance of allergic conjunctivitis in the near future.
The bacterial conjunctivitis segment is anticipated grow at the maximum CAGR through the forecast time-frame mainly due to high prevalence.
Adults Patient Types Dominated the Market Revenue
Conjunctivitis is highly prevalent among the adult population. Augmented exposure to damaging pollutants and substances is resulting in growth in the quantity of conjunctivitis incidence worldwide. People employed in chemical plants and persons exposed to automobile fumes tend to get allergic conjunctivitis. The rising consciousness of the condition and its handling options are driving market growth.
Anti-Histaminic Will Dominate the Conjunctivitis Market Revenue By Drug Class
The prevalent use of anti-histaminic in the effective treatment of conjunctivitis is the key reason for high market share. Steroid Drugs will expand at highest CAGR during the forecast time-frame.
Top Players contending in the Market:
The companies focusing on research and development are expected to lead the global conjunctivitis market. Leading competitors contending in global conjunctivitis market are as follows:
In order to well recognize the present status of conjunctivitis, and policies implemented by the foremost nations, Precedence Research projected the future progress of the conjunctivitis market. This research report bids quantitative and qualitative insights on conjunctivitis market and valuation of market size and progress trend for probable market segments.
Major Market Segments Covered:
By Type
By Patients Type
By Drug Class
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Conjunctivitis Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Conjunctivitis Market
5.1. Covid-19: Conjunctivitis Industry Impact
5.2. Conjunctivitis Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Conjunctivitis Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Conjunctivitis Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Conjunctivitis Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increased exposure to chemicals and pollutants
6.1.1.2. Rising awareness of condition
6.1.2. Market Restraints
6.1.2.1. Lack of Self Awareness
6.1.3. Market Opportunities
6.1.3.1. Exploring specific treatment for viral conjunctivitis
Chapter 7. Global Conjunctivitis Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Conjunctivitis Market Revenue by Market Players
7.1.1.2. Conjunctivitis Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Conjunctivitis Market, By Type
8.1. Conjunctivitis Market, by Type, 2023-2032
8.1.1. Bacterial Conjunctivitis
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Viral Conjunctivitis
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Allergic Conjunctivitis
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Conjunctivitis Market, By Patients Type
9.1. Conjunctivitis Market, by Application, 2023-2032
9.1.1. Pediatric
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Conjunctivitis Market, By Drug Class
10.1. Conjunctivitis Market, by Application, 2023-2032
10.1.1. Antibiotics
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Anti-Histaminic
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Decongestant
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Steroid Drugs
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Conjunctivitis Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue Forecast by Type(2020-2032)
11.1.2. Market Revenue Forecast by Patients Type (2020-2032)
11.1.3. Market Revenue Forecast by Drug Class (2020-2032)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2020-2032)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2020-2032)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2020-2032)
11.2.2. Market Revenue Forecast by Patients Type (2020-2032)
11.2.3. Market Revenue Forecast by Drug Class (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2020-2032)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2020-2032)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2020-2032)
11.3.2. Market Revenue Forecast by Patients Type (2020-2032)
11.3.3. Market Revenue Forecast by Drug Class (2020-2032)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2020-2032)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2020-2032)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2020-2032)
11.4.2. Market Revenue Forecast by Patients Type (2020-2032)
11.4.3. Market Revenue Forecast by Drug Class (2020-2032)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2020-2032)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2020-2032)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2020-2032)
11.5.2. Market Revenue Forecast by Patients Type (2020-2032)
11.5.3. Market Revenue Forecast by Drug Class (2020-2032)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2020-2032)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2020-2032)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2020-2032)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2020-2032)
Chapter 12. Company Profiles
12.1. Atopix Therapeutics Ltd.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Type Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Allegran
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Type Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Ocular Therapeutix, Inc.
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Type Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Santen Pharmaceutical Co. Ltd.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Type Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Novartis
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Type Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Boehringer Ingelheim
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Type Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Boehringer Ingelheim
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Type Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Sun Pharma
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Type Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Sirion Therapeutics, Inc.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Type Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Type Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client